Develops digital therapeutics using video game technology to treat cognitive disorders, such as ADHD.
Akili, Inc., a pioneering digital medicine company, specializes in the development of digital therapeutics aimed at addressing cognitive dysfunction. At the forefront of its offerings is EndeavorRx, a computer-based platform designed to assess and treat cognitive impairments associated with various neurology and psychiatry conditions. These include attention-deficit hyperactivity disorder (ADHD), depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. Akili's innovative solutions employ advanced technologies such as selective stimulus management, body brain training, and spatial navigation engines to target specific cognitive functions like focus, interference processing, memory, and planning.
Based in Boston, Massachusetts, Akili, Inc. is committed to advancing the field of digital therapeutics through rigorous research and development. Its proprietary technologies not only aim to improve cognitive abilities but also enhance overall neurocognitive health across diverse patient populations. The company's strategic location in a hub of medical and technological innovation underscores its dedication to driving transformative advancements in healthcare.
Founded on a mission to harness the power of digital innovation for therapeutic benefit, Akili continues to expand its capabilities and explore new applications for its technologies. With a focus on evidence-based solutions, Akili remains poised to shape the future of cognitive healthcare through its groundbreaking digital therapeutic offerings.